Mean Reduction News Today

Solna, Sweden, December 20, 2023. Affibody’s licensee Rallybio Corporation today announced preliminary Phase 1 multiple ascending dose data for RLYB116, an innovative, long-acting, low volume...

-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing ---- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis ---- Company Announces Extension of Runway to 3Q 2025 As Part of Po...